Source:http://linkedlifedata.com/resource/pubmed/id/18188530
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2008-1-11
|
pubmed:abstractText |
Triglyceride-rich lipoproteins contain both apolipoproteins E (ApoE) and C-III (ApoC-III), which show opposite functional properties. The relationships between the ApoE (epsilon2/epsilon3/epsilon4) gene polymorphism and ApoC-III/ApoE ratio has never been investigated. A large population (n=552) of cardiovascular patients, without diabetes and/or lipid-lowering therapy, with or without metabolic syndrome (MetSyn), was genotyped for epsilon2/epsilon3/epsilon4 polymorphism and their ApoCIII/ApoE ratio was evaluated. A second group of patients (n=76) with peripheral artery disease was also genotyped and their ApoC-III/ApoE ratios were measured in HDL and non-HDL fractions. Subjects with E2 had higher and E4 carriers lower TG,ApoE and ApoC-III levels, respectively. The ApoCIII/ ApoE ratio showed an opposite trend, gradually increasing from E2/E2 to E4/E4 subjects. MetSyn patients also had an elevated ApoC-III/ApoE ratio and E4 carriers were more frequent in MetSyn patients (OR 2.08 with a 95%CI 1.22-3.5). The distribution of ApoC-III/ApoE ratio was confirmed also in the second group, with lower values in E2/E3 and higher in E3/E4 subjects. Similar results were obtained for the concentrations measured in non-HDL fractions, but not in the HDL fractions. ApoE epsilon2/epsilon3/epsilon4 gene polymorphism is a determinant of the relative proportion of apolipoprotein C-III to E. Carriers of the unfavourable E4 allele present the highest ApoCIII/ApoE ratio and are twofold more frequent among individuals affected by MetSyn.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1591-8890
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
164-72
|
pubmed:meshHeading |
pubmed-meshheading:18188530-Adult,
pubmed-meshheading:18188530-Aged,
pubmed-meshheading:18188530-Apolipoprotein C-III,
pubmed-meshheading:18188530-Apolipoprotein E2,
pubmed-meshheading:18188530-Apolipoprotein E3,
pubmed-meshheading:18188530-Apolipoproteins E,
pubmed-meshheading:18188530-Female,
pubmed-meshheading:18188530-Humans,
pubmed-meshheading:18188530-Male,
pubmed-meshheading:18188530-Metabolic Syndrome X,
pubmed-meshheading:18188530-Middle Aged,
pubmed-meshheading:18188530-Polymorphism, Genetic
|
pubmed:year |
2007
|
pubmed:articleTitle |
ApoE epsilon2/epsilon3/epsilon4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome.
|
pubmed:affiliation |
Unit of Internal Medicine, Department of Clinical and Experimental Medicine, Cattedra di Medicina Interna, University of Verona, Policlinico Borgo Roma, 37134, Verona, Italy. oliviero.olivieri@univr.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|